WO2022206086A1 - 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 - Google Patents
靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 Download PDFInfo
- Publication number
- WO2022206086A1 WO2022206086A1 PCT/CN2022/000056 CN2022000056W WO2022206086A1 WO 2022206086 A1 WO2022206086 A1 WO 2022206086A1 CN 2022000056 W CN2022000056 W CN 2022000056W WO 2022206086 A1 WO2022206086 A1 WO 2022206086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- herpes virus
- plaster
- targeted
- plaster composition
- herpes
- Prior art date
Links
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 84
- 239000011505 plaster Substances 0.000 title claims abstract description 53
- 230000002779 inactivation Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims abstract description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 20
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims abstract description 20
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 15
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 15
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 12
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001630 malic acid Substances 0.000 claims abstract description 12
- 235000011090 malic acid Nutrition 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 12
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 11
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004029 silicic acid Drugs 0.000 claims abstract description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 11
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 11
- 239000000600 sorbitol Substances 0.000 claims abstract description 11
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 10
- 239000004317 sodium nitrate Substances 0.000 claims abstract description 10
- 235000010344 sodium nitrate Nutrition 0.000 claims abstract description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 10
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 9
- 229920013818 hydroxypropyl guar gum Polymers 0.000 claims abstract description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 9
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims abstract description 9
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims abstract description 9
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 8
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 8
- 229940052490 naringin Drugs 0.000 claims abstract description 8
- 229930019673 naringin Natural products 0.000 claims abstract description 8
- 239000004323 potassium nitrate Substances 0.000 claims abstract description 8
- 235000010333 potassium nitrate Nutrition 0.000 claims abstract description 8
- 229960004711 sodium monofluorophosphate Drugs 0.000 claims abstract description 8
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 8
- 235000019801 trisodium phosphate Nutrition 0.000 claims abstract description 8
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims abstract description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 6
- 239000004698 Polyethylene Substances 0.000 claims abstract description 6
- -1 polyethylene Polymers 0.000 claims abstract description 6
- 229920000573 polyethylene Polymers 0.000 claims abstract description 6
- 239000000230 xanthan gum Substances 0.000 claims abstract description 6
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 6
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 6
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 34
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 23
- 239000006072 paste Substances 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 10
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 201000004946 genital herpes Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 230000003020 moisturizing effect Effects 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 206010059313 Anogenital warts Diseases 0.000 claims description 4
- 208000006558 Dental Calculus Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 108700004121 sarkosyl Proteins 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 241000332371 Abutilon x hybridum Species 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- ULVJUOMUAAYMKJ-UHFFFAOYSA-L strontium;dichloride;hydrate Chemical compound O.[Cl-].[Cl-].[Sr+2] ULVJUOMUAAYMKJ-UHFFFAOYSA-L 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 239000000686 essence Substances 0.000 abstract description 3
- 229940001516 sodium nitrate Drugs 0.000 abstract description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 abstract 1
- 241000717662 Clinopodium chinense Species 0.000 abstract 1
- 229940085605 saccharin sodium Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- 201000006082 Chickenpox Diseases 0.000 description 7
- 206010046980 Varicella Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 241000123667 Campanula Species 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000703121 Campanula rotundifolia Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000511536 Radix auricularia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the invention relates to the technical field of pharmaceutical preparations, in particular to a targeted inactivated herpes virus plaster composition for treating herpes virus, a preparation method thereof, and use of the plaster composition in the preparation of a targeted inactivated herpes virus medicament.
- Herpesviruses are a group of enveloped DNA viruses with similar biological properties, classified as herpesviruses. A total of more than 100 kinds of herpes viruses have been found, which can be divided into a, b, y three categories (subfamilies) and other herpes viruses, which infect a wide range of hosts, mainly invading skin, mucous membranes and nerve tissue, seriously affecting the health of humans and other animals. . Quoting Wikipedia. Virus is a kind of non-cellular organisms that are small in size, simple in structure, contain only one nucleic acid (RNA or DNA), and must be parasitic in living cells and reproduce by means of replication. Quoting Wikipedia.
- Herpes virus is one or more selected from: herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus type 6, human herpes virus type 7, human Herpes virus type 8, AIDS, genital herpes, herpes virus.
- the targeted drug of the present invention has the efficacy of inactivating herpes virus in the human body, and after many trials in humans, it can effectively treat the herpes virus without serious side effects.
- the targeted inactivation herpes virus patch composition of the invention comprises patch, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, essence, sodium saccharin, naringin, campanula extract, yellow Original Gum, Polyethylene Glycol-8, Calcium Carbonate, Hydroxyethyl Cellulose, Hydroxypropyl Guar Gum, Sodium Nitrate, Hydrated Silica, Sodium Lauryl Sulfate, Appropriate Purified Water, Strontium Chloride Hexahydrate, A combination of tranexamic acid, two-sided needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, and sodium chloride.
- Dosage regimens of ingredients implemented in the pharmaceutical compositions of the present invention are based on a variety of factors, including patient type, age, herpesvirus infection, weight, gender and medical condition, the severity of the condition, the route of administration, and the activity of the particular compound employed, including . Therefore, the dosage of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- the friction agent is one or more of calcium carbonate, calcium hydrogen phosphate, hydrated silica, calcium pyrophosphate, aluminum hydroxide, and friction agent, and its weight percentage is 1% to 50%;
- the surfactant is one or more of sodium lauryl sulfate, lauroyl sarcosine, polysorbate derivatives, and surfactant, and its weight percentage is 0.1% to 3%;
- the preservative is one or more of parabens, sodium benzoate, and preservatives, and its weight percentage is 0.05% to 0.2%;
- the essence is one or more of essence, mint and essence, and its weight percentage is 0.5% to 1.5%;
- the sweetener is one or more of sodium saccharin and sweetener, and its weight percentage is 0.1% to 1%;
- the thickener is one or more of hydroxyethyl cellulose, xanthan gum, trisodium phosphate, cellulose gum, and thickener, and its weight percentage is 0.05% to 4%;
- the moisturizing agent is one or more of sorbitol, xylitol, polyethylene glycol-8, and moisturizing agent, and its weight percentage is 5% to 21%;
- the adhesive is one or more of hydroxypropyl guar gum and adhesive, and its weight percentage is 0.05% to 1%; paste: paste, paste, paste, thin paste that can be cut according to the size of the affected area , and various thin stickers.
- the pharmaceutical composition of the present invention comprises patch, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, essence, sodium saccharin, naringin, bellflower extract, xanthan gum, polyethylene glycol Alcohol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, purified water, strontium chloride hexahydrate, tranexamic acid, lichen extract Compound, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride.
- Dosage regimens of ingredients implemented in the pharmaceutical compositions of the present invention are based on a variety of factors, including patient type, age, herpesvirus infection, weight, gender and medical condition, the severity of the condition, the route of administration, and the activity of the particular compound employed, including .
- the dosage regimen of the ingredients in the present invention can vary widely to give the best therapeutic effect to the patient.
- Example 1 paste, malic acid 1%, sorbitol 20%, calcium carbonate 36%, hydroxyethyl cellulose 1%, sodium benzoate 0.2%, cellulose gum 0.5%, hydroxypropyl guar gum 1%, Flavor 1%, sodium saccharin 0.46%, sodium nitrate 0.2%, hydrated silica 14%, sodium lauryl sulfate 2.8%, appropriate amount of purified water, strontium chloride hexahydrate 0.8%, tranexamic acid 0.5%.
- This example is a test formulation included in the present invention.
- the dosage regimen of the components implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, and the severity of the condition. The extent, route of administration, and activity of the particular compound employed. Therefore, the dosage regimen of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- Example 2 paste, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, Flavor 1%, sodium saccharin 0.36%, sodium nitrate 0.3%, hydrated silica 10%, sodium lauryl sulfate 3%, appropriate amount of purified water, strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%.
- This example is a test formulation included in the present invention.
- the dosage regimen of the components implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, and the severity of the condition. The extent, route of administration, and activity of the particular compound employed. Therefore, the dosage regimen of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- Example 3 paste, malic acid 1.5%, sorbitol 21%, calcium carbonate 45%, hydroxyethyl cellulose 0.7%, sodium benzoate 0.18%, cellulose gum 0.7%, hydroxypropyl guar gum 0.7%, Flavor 0.7%, sodium saccharin 0.35%, sodium nitrate 0.3%, hydrated silica 5%, sodium lauryl sulfate 2.7%, appropriate amount of purified water, strontium chloride hexahydrate 0.75%, tranexamic acid 0.6%.
- This example is a test formulation included in the present invention.
- the dosage regimen of the components implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, and the severity of the condition. The extent, route of administration, and activity of the particular compound employed. Therefore, the dosage regimen of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- Example 4 paste, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, essence 0.9%, sodium saccharin 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, lauryl alcohol Sodium Fatty Sulfate 2.8%, Appropriate amount of Purified Water, Radix Auricularia Extract 2%, Naringin 0.6%, Campanula Extract 1.5%, Xanthan Gum 0.6%, (Polyethylene Glycol-8) 2%.
- This example is a test formulation included in the present invention.
- the dosage regimen of the components implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection, age, weight, gender and medical condition, and the severity of the condition. The extent, route of administration, and activity of the particular compound employed. Therefore, the dosage regimen of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- Example 5 paste, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, essence 0.8%, sodium saccharin 0.36%, hydrated silica 12%, lauryl sulfate Lipid sodium 2.9%, purified water appropriate amount, sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 1.6%, trisodium phosphate 0.36%, sodium chloride 0.5%.
- This example is a test formulation included in the present invention.
- the dosage regimen of the components implemented in the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, and the severity of the condition. The extent, route of administration, and activity of the particular compound employed. Therefore, the dosage regimen of the ingredients in the present invention can be varied widely to give the best therapeutic effect to the patient.
- Example 1 and Example 4 When the herpes virus is recurring, severe and drug-resistant, the combination of Example 1 and Example 4 is used successively.
- the combination one embodiment changes the combination for one day.
- the drug does not cause serious side effects to the patient.
- the dosage of the medicinal components is prepared within the required dosage range of each type of component, and the daily human dose is prepared within the required dosage range, and it is a drug that does not cause serious side effects to the patient.
- Example 2 and Example 4 are used in combination successively.
- one embodiment changes the combination medication one day, and when the combination medication is used, it does not cause serious side effects to the patient.
- the dosage of the medicinal components is prepared within the required dosage range of each type of component, and the daily human dose is prepared within the required dosage range, and it is a drug that does not cause serious side effects to the patient.
- the combination of Example 3 and Example 4 is used successively. When the combination is used, one embodiment changes the combination for one day. When the combination is used, the drug does not cause serious side effects to the patient.
- the dosage of the medicinal components is prepared within the required dosage range of each type of component, and the daily human dose is prepared within the required dosage range, and it is a drug that does not cause serious side effects to the patient.
- Herpesviruses are a group of enveloped DNA viruses with similar biological characteristics, classified as herpesviruses, genital herpesviruses are a type of herpesviruses, and herpesviruses are a type of viruses.
- the second test the genital herpes is gone, the skin is a little red. Herpes varicella decreased by two when seeing herpes in relapsers.
- the third test the genital herpes is gone, the skin is a little red. Herpes varicella decreased by three when seeing herpes in relapsers.
- the fourth test the genital herpes was gone, and the skin was a little red.
- Herpes chickenpox is gone... It is because the ingredients and doses are different that the results of the first experiment are different. After many tests, in order to change the effect, other ingredients and doses were used. During the test, the herpes chickenpox disappeared, and the severe herpes time will be prolonged. . . If the plaster is applied for a long time, it will cause slight dehydration of the skin.
- herpes chickenpox will disappear. less treatment time than existing drugs. Drugs that can effectively treat herpes virus-related diseases without serious side effects.
- a 2-cent coin-sized object appears on the waist, which is not the same as the skin, and it is uneven. Herpes chickenpox reduction. The skin is sometimes smooth as it recovers. Reddish. Over time, it will cause slight dehydration of the skin.
- the first discovery of the efficacy of herpes treatment is an accidental discovery, which can make herpes chickenpox disappear in the body. After many trials in humans, because the drug has the effect of treating herpes virus in the human body. be the applicant.
- the drug is processed into water, solution, injection, mixture, lotion, liniment, aerosol, spray, powder, pill, tablet, film, capsule, ointment, suppository, paste Various dosage forms of medicines.
- the present invention contains the active ingredient of herpes virus.
- the drug is transdermally administered according to the size of the disease site, and the plaster is pasted. At the infected site, it penetrates through the skin and reaches the subcutaneous tissue, resulting in a relative advantage of drug concentration at the disease site, thereby exerting a stronger pharmacological effect. effect. After passing through the skin and mucous membranes, it enters the human circulation through blood vessels and lymphatic vessels, and can also produce systemic drug effects. Under the action of the paste, the drug exerts a stronger pharmacological effect. Specific and precise inactivation of latent herpes virus in vivo. It has no serious side effects on normal cells and normal tissues of the body.
- plaster pharmaceutical composition in the preparation of targeted inactivated herpes virus drugs: tumor, venereal disease, tartar removal, hepatitis, pneumonia, new coronary pneumonia, AIDS, condyloma acuminatum, fungal disease, lupus erythematosus, anthrax, palm and toe pus
- Herpes disease cancer, herpes simplex virus, herpes virus, EB virus, virus, syphilis, tartar removal, virus characterized, new coronary pneumonia, AIDS, condyloma acuminatum, herpes characterized disease, virus
- the present invention can prepare various dosage forms of water, solution, injection, mixture, lotion, liniment, aerosol, spray, powder, pill, tablet, film, capsule, ointment, suppository and paste drug.
- the present invention can be easily modified for practitioners in the medical field. Any other changes, modifications, substitutions, moves, mergers, improvements, changes, optimizations, combinations, simplifications, processing, refinements, imitations, stealing concepts, and deepening that do not deviate from the spirit and principles of the present invention shall be Equivalent replacement. All are included in the protection scope of the present invention.
- the compositions, methods, dosages, products, uses and technical solutions of the present invention are all within the scope of protection.
- the same product, similar product, same method, similar method, similar technique, same technique, same ingredient, similar ingredient, same ingredient dosage, and similar ingredient dosage as the ingredients of the plaster in the pharmaceutical composition of the present invention are in the preparation target.
- herpes virus drugs hepatitis, pneumonia, cancer, fungal disease, lupus erythematosus, anthrax, skin tumors, palmar toe abscesses, tumors, venereal diseases, herpes simplex virus, herpes virus, EB virus, virus, syphilis , tartar removal, new coronary pneumonia, AIDS, condyloma acuminatum, virus is characterized, herpes is characterized, herpes virus, virus is within the scope of protection
- the drug-protected ingredients that target the inactivation of the herpes virus are 0-100%
- Herpes virus is one or more selected from: herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus type 6, human herpes virus type 7, human Herpes virus type 8, AIDS, genital herpes, herpes virus.
Abstract
靶向灭活疱疹病毒膏贴组合物包含有贴、磷酸三钠、苹果酸、山梨糖醇、苯甲酸钠、纤维素胶、香精、糖精钠、柚皮苷、风轮草提取物、黄原胶、聚乙二醇-8、碳酸钙、羟乙基纤维素、羟丙基瓜儿胶、硝酸钠、水合硅石、月桂醇硫酸脂钠、纯净水适量、氯化锶六水合物、凝血酸、两面针提取物、单氟磷酸钠、海盐、硝酸钾和氯化钠。
Description
本发明涉及医药制剂技术领域，具体涉及一种治疗疱疹病毒的靶向灭活疱疹病毒膏贴组合物及其制备方法和膏贴组合物在制备靶向灭活疱疹病毒药物中的用途。
疱疹病毒是一群有包膜的DNA病毒，生物学特性相似，归类为疱疹病毒。总共发现了100多种，可以分为a、b、y三大类(亚科)以及其他疱疹病毒，其感染宿主广泛，主要侵害皮肤、黏膜以及神经组织，严重影响着人及其他动物的健康。引用百度百科。病毒是一种个体微小，结构简单，只含一种核酸(RNA或DNA)，必须在活细胞内寄生并以复制方式增殖的非细胞型生物。引用百度百科。
疱疹病毒为选自其中的一种或多种：单纯疱疹病毒1型、单纯疱疹病毒2型、水痘带状疱疹、EB病毒、巨细胞病毒、人类疱疹病毒6型、人类疱疹病毒7型、人类疱疹病毒8型、艾滋病、生殖器疱疹、疱疹病毒。
目前，药物治疗疱疹病毒易复发，治疗时间长，有副作用。需要一种可以有效治疗疱疹病毒相关疾病而不造成严重副作用的药物
发明内容
在一个偶然的机会，申请人意外的发现，本发明靶向药物在人体内有灭活疱疹病毒的药效，又经过多次在人体试验，可以有效治疗疱疹病毒，并且没有严重副作用。
发明的靶向灭活疱疹病毒膏贴组合物包含有贴、磷酸三钠、苹果酸、山梨糖醇、苯甲酸钠、纤维素胶、香精、糖精钠、柚皮苷、风轮草提取物、黄原胶、聚乙二醇——8、碳酸钙、羟乙基纤维素、羟丙基瓜儿胶、硝酸钠、水合硅石、月桂 醇硫酸脂钠、纯净水适量、氯化锶六水合物、凝血酸、两面针提取物、单氟磷酸钠、海盐、硝酸钾、氯化钠组合制成。本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、年龄、疱疹病毒感染情况、重量、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量可以广泛变化，给患者最佳的治疗效果。
摩擦剂为碳酸钙、磷酸氢钙、水合硅石、焦磷酸钙、氢氧化铝、摩擦剂中一种或多种，其重量百分比为1％～50％；
表面活性剂为月桂醇硫酸脂钠、月桂酰肌氨酸、聚山梨醇酯类衍生物、表面活性剂中一种或多种，其重量百分比为0.1％～3％；
防腐剂为对羟基苯甲酸脂类、苯甲酸钠、防腐剂中一种或多种，其重量百分比为0.05％～0.2％；
香精为香精、薄荷、香精中一种或多种，其重量百分比为0.5％～1.5％；
甜味剂为糖精钠、甜味剂中一种或多种，其重量百分比为0.1％～1％；
增稠剂为羟乙基纤维素、黄原胶、磷酸三钠、纤维素胶、增稠剂中一种或多种，其重量百分比为0.05％～4％；
保湿剂为山梨糖醇、木糖醇、聚乙二醇-8、保湿剂中一种或多种，其重量百分比为5％～21％；
粘合剂为羟丙基瓜儿胶、粘合剂中一种或多种，其重量百分比为0.05％～1％；贴：膏贴、贴、膏、可以根据患处位置大小需要剪的薄贴、及各种薄贴。
其他：硝酸钠0.05％～0.4％、两面针提取物0.1％～4.3％、纯净水适量、氯化锶六水合物0.1％～2.5％、凝血酸0.1％～2％、贴、柚皮苷0.002％～2％、风轮草提取物0.01％～3％、苹果酸0.08％～2.5％、单氟磷酸钠0.001％～1％、海盐0.01％～0.9％、 硝酸钾0.05％～2％、氯化钠0.01％～0.9％、贴。
本发明的药物组合物包含有贴、磷酸三钠、苹果酸、山梨糖醇、苯甲酸钠、纤维素胶、香精、糖精钠、柚皮苷、风轮草提取物、黄原胶、聚乙二醇——8、碳酸钙、羟乙基纤维素、羟丙基瓜儿胶、硝酸钠、水合硅石、月桂醇硫酸脂钠、纯净水适量、氯化锶六水合物、凝血酸、两面针提取物、单氟磷酸钠、海盐、硝酸钾、氯化钠制成。本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、年龄、疱疹病毒感染情况、重量、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，为给患者最佳的治疗效果，本发明里成分剂量方案可以广泛变化。
实施方式
依据以下实施例是描述本发明，而不应经此限制本发明的范围：
实施例1：贴、苹果酸1％、山梨糖醇20％、碳酸钙36％、羟乙基纤维素1％、苯甲酸钠0.2％、纤维素胶0.5％、羟丙基瓜儿胶1％、香精1％、糖精钠0.46％、硝酸钠0.2％、水合硅石14％、月桂醇硫酸脂钠2.8％、纯净水适量、氯化锶六水合物0.8％、凝血酸0.5％。本实施例是本发明包含的试验例配，本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、年龄、重量、疱疹病毒感染情况、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量方案可以广泛变化，给患者最佳的治疗效果。
实施例2：贴、苹果酸1.8％、山梨糖醇20％、碳酸钙40％、羟乙基纤维素1％、苯甲酸钠0.16％、纤维素胶0.5％、羟丙基瓜儿胶0.98％、香精1％、糖精钠0.36％、硝酸钠0.3％、水合硅石10％、月桂醇硫酸脂钠3％、纯净水适量、氯化锶六水合物0.65％、凝血酸0.5％。本实施例是本发明包含的试验例配，本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、年龄、重量、疱疹 病毒感染情况、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量方案可以广泛变化，给患者最佳的治疗效果。
实施例3：贴、苹果酸1.5％、山梨糖醇21％、碳酸钙45％、羟乙基纤维素0.7％、苯甲酸钠0.18％、纤维素胶0.7％、羟丙基瓜儿胶0.7％、香精0.7％、糖精钠0.35％、硝酸钠0.3％、水合硅石5％、月桂醇硫酸脂钠2.7％、纯净水适量、氯化锶六水合物0.75％、凝血酸0.6％。本实施例是本发明包含的试验例配，本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、年龄、重量、疱疹病毒感染情况、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量方案可以广泛变化，给患者最佳的治疗效果。
实施例4：贴、苹果酸1.5％、山梨糖醇18％、苯甲酸钠0.15％、纤维素胶1％、香精0.9％、糖精钠0.35％、磷酸三钠0.4％、水合硅石36％、月桂醇硫酸脂钠2.8％、纯净水适量、两面针提取物2％、柚皮苷0.6％、风轮草提取物1.5％、黄原胶0.6％、(聚乙二醇——8)2％。本实施例是本发明包含的试验例配，本发明药物组合物所实施的成分剂量方案，基于多种因素，包括患者类型、疱疹病毒感染情况、年龄、重量、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量方案可以广泛变化，给患者最佳的治疗效果。
实施例5：贴、苹果酸1.3％、山梨糖醇21％、碳酸钙38％、苯甲酸钠0.16％、纤维素胶0.7％、香精0.8％、糖精钠0.36％、水合硅石12％、月桂醇硫酸脂钠2.9％、纯净水适量、单氟磷酸钠0.8％、海盐0.3％、硝酸钾1.6％、磷酸三钠0.36％、氯化钠0.5％。本实施例是本发明包含的试验例配，本发明药物组合物所实施的成 分剂量方案，基于多种因素，包括患者类型、年龄、重量、疱疹病毒感染情况、性别和医疗状况，病况的严重程度，施用途径，以及所用包含特定化合物的活性。因此，本发明里成分剂量方案可以广泛变化，给患者最佳的治疗效果。
疱疹病毒在复发、严重、耐药时，实施例1和实施例4先后联合用药，联合用药时一个实施例一天换着先后联合用药，联合用药时，不给患者造成严重副作用的药物。同时联合用药时，药物成分剂量按每类成分剂量要求范围内配制并且每天人体使用剂量在要求用量范围配制，不给患者造成严重副作用的药物。疱疹病毒在复发、严重、耐药时，实施例2和实施例4先后联合用药，联合用药时一个实施例一天换着先后联合用药，联合用药时，不给患者造成严重副作用的药物。同时联合用药时，药物成分剂量按每类成分剂量要求范围内配制并且每天人体使用剂量在要求用量范围配制，不给患者造成严重副作用的药物。疱疹病毒在复发、严重、耐药时，实施例3和实施例4先后联合用药，联合用药时一个实施例一天换着先后联合用药，联合用药时，不给患者造成严重副作用的药物。同时联合用药时，药物成分剂量按每类成分剂量要求范围内配制并且每天人体使用剂量在要求用量范围配制，不给患者造成严重副作用的药物。
疱疹病毒是一群有包膜的DNA病毒，生物学特性相似，归类为疱疹病毒，生殖器疱疹病毒属于疱疹病毒的一种，疱疹病毒属于病毒的一种。
申请人在某一天意外的发现，因脚上长了一个黑色的疙瘩，长得速度蛮快，我用小刀割开，里面有血丝，我就用牙膏贴在上面，过了几天，撕下贴，肉疙瘩没见了，只剩一个小洞口。我就觉得有别的用处。
申请人意外发现，第一次试验在生殖器疱疹上面，贴上膏贴，撕下时，生殖器疱疹没有了，皮肤有点红，腰部出现了一个和皮肤不一样2分硬币大小的东西。第二次试验，生殖器疱疹没有了，皮肤有点红。看到复发者疱疹时，疱疹水痘减少两个。第三次试验，生殖器疱疹没有了，皮肤有点红。看到复发者疱疹时，疱疹水痘减少三个。第四次试验，生殖器疱疹没有了，皮肤有点红。疱疹水痘没有了...是成分和剂量不一样造成和第一次实验结果不一样。经过多次试验，为了改变效果，用了别的成分和剂量，试验时，疱疹水痘就没有了，严重的疱疹时间会延长。。。膏贴贴时间长了，会造成皮肤轻微脱水现象。
在单纯疱疹上试验，皮肤有水痘，贴上膏贴，水痘没有了，恢复时皮肤微红。时间长了，会造成皮肤脱水现象。试验就不再一一描述。
经过在疱疹病毒多次试验，现在，疱疹水痘都是会消失。比现有药物治疗时间少。可以有效治疗疱疹病毒相关疾病而不造成严重副作用的药物。
特征：腰部出现了一个和皮肤不一样2分硬币大小的东西，上面不平。疱疹水痘减少。皮肤在恢复时，有时光滑。微红.时间长了，会造成皮肤轻微脱水现象。第一次发现治疗疱疹药效是意外发现，可以使体内疱疹水痘消失。经过多次在人体试验，因为药物在人体内有治疗疱疹病毒的药效。才成为申请人。
药物组合物的制备方法
准备好混合容器、装膏用的软管状用品；
1，先把粉状化合物用粉碎机粉碎均匀，等候使用。
2、取配方量少量纯净水、山梨糖醇、月桂醇硫酸脂钠，倒入混合容器中，用搅拌机搅拌均匀。等发泡以后使用。
3、再加入苹果酸、碳酸钙、水合硅石、羟丙基瓜儿胶、纤维素胶、羟乙基纤维 素、硝酸钠、磷酸三钠、氯化锶六水合物、凝血酸、两面针提取物、柚皮苷、聚乙二醇-8、风轮草提取物、黄原胶、单氟磷酸钠、海盐、硝酸钾、氯化钠继续搅拌均匀。根据混合物的稀稠加入纯净水，直到达标为止。等20分钟后，加入香精、糖精钠、苯甲酸钠继续搅拌均匀。抽去真空。
4、最后把药物加工制作水剂、溶液剂、注射剂、合剂、洗剂、搽剂、气雾剂、喷雾剂、散剂、丸剂、片剂、膜剂、胶囊剂、软膏剂、栓剂、糊剂各种剂型药品。
5、本发明包含有疱疹病毒的活性成分。
在临床上确诊疱疹病毒感染部位后，根据疾病部位大小经皮给药，贴上膏贴，在感染处通过皮肤渗透达皮下组织，在疾病部位产生药物浓度的相对优势，从而发挥更强的药理作用。通过皮肤及黏膜后，经过血管和淋巴管进入人体循环，也可产生全身性药物作用。药物在贴的作用下，从而发挥更强的药理作用。对体内潜伏疱疹病毒特异性精准灭活。对身体正常细胞、身体正常组织没有严重副作用，
膏贴药物组合物在制备靶向灭活疱疹病毒药物中的用途：肿瘤、性病类、清牙垢、肝炎、肺炎、新冠肺炎、艾滋病、尖锐湿疣、真菌病、红斑狼疮、炭疽病、掌趾脓疱病、癌症、单纯疱疹病毒、疱疹病毒、EB病毒、病毒、梅毒、清牙垢、病毒为特征、新冠肺炎、艾滋病、尖锐湿疣、疱疹为特征的疾病、病毒
本发明可以制作水剂、溶液剂、注射剂、合剂、洗剂、搽剂、气雾剂、喷雾剂、散剂、丸剂、片剂、膜剂、胶囊剂、软膏剂、栓剂、糊剂各种剂型药品。
本发明对于医务领域工作者来说，可以轻易地对其修改。其他的任何未背离本发明的精神实质与原理下所做的改变、修饰、替换、移动、合并、改进、变化、优化、组合、简化、加工、提炼、仿制、偷换概念、深化均应为等效的置换方 式。都包含在本发明的保护范围之内。本发明的成分、方法、剂量、产品、用途、技术方案都在保护范围之内。和本发明药物组合物里膏的成分相同产品、相似产品、相同方法、相似方法、相似技术、相同技术、相同成分、相似成分、相同成分剂量、相似成分剂量的膏贴药物组合物在制备靶向灭活疱疹病毒药物中的用途：肝炎、肺炎、癌症、真菌病、红斑狼疮、炭疽病、皮肤肿瘤掌趾脓包疮、肿瘤、性病类、单纯疱疹病毒、疱疹病毒、EB病毒、病毒、梅毒、清牙垢、新冠肺炎、艾滋病、尖锐湿疣、病毒为特征、疱疹为特征、疱疹病毒、病毒在保护范围之内
靶向灭活疱疹病毒的药物保护成分是0-100％
疱疹病毒为选自其中的一种或多种：单纯疱疹病毒1型、单纯疱疹病毒2型、水痘带状疱疹、EB病毒、巨细胞病毒、人类疱疹病毒6型、人类疱疹病毒7型、人类疱疹病毒8型、艾滋病、生殖器疱疹、疱疹病毒。
Claims (28)
- 一种靶向灭活疱疹病毒膏贴组合物。其特征是，所述靶向灭活疱疹病毒膏贴组合物包含有贴、苹果酸0.08％～2.5％、硝酸钠0.05％～0.4％、两面针提取物0.1％～4.3％、纯净水适量、氯化锶六水合物0.1％～2.5％、凝血酸0.1％～2％、柚皮苷0.002％～2％、风轮草提取物0.01％～3％、单氟磷酸钠0.001％～1％、海盐0.01％～0.9％、硝酸钾0.05％～2％、氯化钠0.01％～0.9％、摩擦剂1％～50％、表面活性剂0.1％～3％、防腐剂0.05％～0.2％、香精0.5％～1.5％、甜味剂0.1％～1％、增稠剂0.05％～4％、保湿剂5％～21％、粘合剂0.05％～1％制成。
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，摩擦剂为碳酸钙、磷酸氢钙、水合硅石、焦磷酸钙、氢氧化铝、摩擦剂中一种或多种，其重量百分比为1％～50％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，表面活性剂为月桂醇硫酸脂钠、月桂酰肌氨酸、聚山梨醇酯类衍生物、表面活性剂中一种或多种，其重量百分比为0.1％～3％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，防腐剂为对羟基苯甲酸脂类、苯甲酸钠、防腐剂中一种或多种，其重量百分比为0.05％～0.2％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，香精为香精、薄荷、香精中一种或多种，其重量百分比为0.5％～1.5％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，甜味剂为糖精钠、甜味剂中一种或多种，其重量百分比为0.1％～1％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，增稠剂为羟 乙基纤维素、磷酸三钠、黄原胶、纤维素胶、增稠剂中一种或多种，其重量百分比为0.05％～4％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，保湿剂为山梨糖醇、木糖醇、聚乙二醇-8、保湿剂中一种或多种，其重量百分比为5％～21％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，粘合剂为羟丙基瓜儿胶、粘合剂中一种或多种，其重量百分比为0.05％～1％；
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，贴：膏贴、贴、膏、可以根据患处位置大小需要剪的薄贴、及各种薄贴。
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物，其特征是，其他：硝酸钠0.05％～0.4％、两面针提取物0.1％～4.3％、纯净水适量、氯化锶六水合物0.1％～2.5％、凝血酸0.1％～2％、柚皮苷0.002％～2％、风轮草提取物0.01％～3％、苹果酸0.08％～2.5％、贴、单氟磷酸钠0.001％～1％、海盐0.01％～0.9％、硝酸钾0.05％～2％、氯化钠0.01％～0.9％
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向药物进入体内，特异性精准和疱疹病毒相结合发生作用，并在目标部位蓄积或释放有效成分，药物在贴的作用下在目标局部形成相对较高的浓度，在提高药效的同时灭活疱疹病毒，对身体正常细胞、正常组织无严重副作用。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，本发明的靶向药物包含有多种疾病的活性成分。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、 17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，疱疹病毒为选自以下的一种或多种：单纯疱疹病毒1型、单纯疱疹病毒2型、水痘带状疱疹、EB病毒、巨细胞病毒、人类疱疹病毒6型、人类疱疹病毒7型、人类疱疹病毒8型、艾滋病、生殖器疱疹、疱疹病毒
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向灭活疱疹病毒膏贴组合物的制备方法在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，膏指靶向药物。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，贴指靶向药物，
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，首创靶向灭活疱疹病毒膏贴药物在制药中的新用途也在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向灭活疱疹病毒膏贴组合物在制备靶向灭活疱疹病毒药物中的用途：红斑狼疮、炭疽病、天疱疮、皮肤肿瘤、掌趾脓疱病、肿瘤、单纯疱疹病毒、疱疹病毒、病毒、梅毒、清牙垢、新冠肺炎、艾滋病、尖锐湿 疣、肝炎、肺炎、疱疹为特征的疾病、病毒感染为特征的疾病都在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向灭活疱疹病毒膏贴组合物在制备靶向灭活疱疹病毒药物中有：艾滋病病毒、癌细胞、肿瘤、肿瘤细胞、致瘤因子、肝炎肺炎、病毒、疱疹病毒、真菌、病毒感染为特征疾病的活性成分。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，注射、介入治疗、靶向药物、感染部位给药、其他经皮给药。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，牙膏成分，辅料成分
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向灭活疱疹病毒膏贴组合物可以制作水剂、溶液剂、注射剂、合剂、洗剂、搽剂、气雾剂、喷雾剂、散剂、丸剂、片剂、膜剂、胶囊剂、软膏剂、栓剂、糊剂各种不同的剂型药剂。任何仿制，都是进入保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，实施例实验的剂量是描述本发明，而不应经此限制本 发明的范围。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，实施例实验的成分是描述本发明，而不应经此限制本发明的范围。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，本发明为给患者最佳的治疗效果，不受实施例上成分剂量的限制，而是根据患者年龄、疱疹病毒感染情况、施用途径、以及所用包含特定药品的活性、病情严重程度及各种因素，因此，成分剂量方案可以广泛变化。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，成分剂量要求保护范围是0-100％。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物，其特征是，靶向灭活疱疹病毒膏贴组合物治疗疱疹病毒比现有药物治疗时间少。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202280006407.8A CN116583267A (zh) | 2021-04-19 | 2022-03-29 | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110416934.3 | 2021-04-19 | ||
| CN202110416934 | 2021-04-19 | ||
| CN2021000191 | 2021-09-18 | ||
| CNPCT/CN2021/000191 | 2021-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022206086A1 true WO2022206086A1 (zh) | 2022-10-06 |
Family
ID=83457874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/000056 WO2022206086A1 (zh) | 2021-04-19 | 2022-03-29 | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116583267A (zh) |
| WO (1) | WO2022206086A1 (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101057953A (zh) * | 2006-04-21 | 2007-10-24 | 陈祖辉 | 对付病毒感染疾患的多靶协同防治制剂 |
| CN102525871A (zh) * | 2012-03-13 | 2012-07-04 | 常熟华港制药有限公司 | 用于预防和治疗复发性口疮的牙膏及制备方法 |
| CN104258067A (zh) * | 2014-09-12 | 2015-01-07 | 皖南医学院 | 一种用于巴布剂的药物组合物、巴布剂及其制备工艺 |
| CN105055230A (zh) * | 2015-08-11 | 2015-11-18 | 刘三猫 | 一种多功用的中药牙膏组合物及其牙膏和制备方法 |
| CN108379139A (zh) * | 2018-03-07 | 2018-08-10 | 济川药业集团有限公司 | 一种防治口腔溃疡的牙膏及其制备方法和应用 |
-
2022
- 2022-03-29 WO PCT/CN2022/000056 patent/WO2022206086A1/zh active Application Filing
- 2022-03-29 CN CN202280006407.8A patent/CN116583267A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101057953A (zh) * | 2006-04-21 | 2007-10-24 | 陈祖辉 | 对付病毒感染疾患的多靶协同防治制剂 |
| CN102525871A (zh) * | 2012-03-13 | 2012-07-04 | 常熟华港制药有限公司 | 用于预防和治疗复发性口疮的牙膏及制备方法 |
| CN104258067A (zh) * | 2014-09-12 | 2015-01-07 | 皖南医学院 | 一种用于巴布剂的药物组合物、巴布剂及其制备工艺 |
| CN105055230A (zh) * | 2015-08-11 | 2015-11-18 | 刘三猫 | 一种多功用的中药牙膏组合物及其牙膏和制备方法 |
| CN108379139A (zh) * | 2018-03-07 | 2018-08-10 | 济川药业集团有限公司 | 一种防治口腔溃疡的牙膏及其制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| HAO JING , ZHANG MEIYING , WANG YIFEI , WANG YAFENG , WANG XIAOYAN , PEI YING , YANG KE , QIAN TRAIWEN , ZHANG YINGJUN , YANG CHON: "Experimental study on the anti-herpes simplex virus type 1 activity of 41 kinds of southern medicine extracts", JOURNAL OF CHINESE MEDICINAL MATERIALS, vol. 31, no. 8, 25 August 2008 (2008-08-25), pages 1226 - 1229, XP055974159, ISSN: 1001-4454, DOI: 10.13863/j.issn1001-4454.2008.08.045 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116583267A (zh) | 2023-08-11 |
| CN116583267A8 (zh) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375037B2 (ja) | 生薬等含有医薬組成物（肆） | |
| US9782426B2 (en) | Anti-viral therapeutic composition | |
| JP6622217B2 (ja) | 過酸化物製剤ならびにその使用のための方法および塗布器 | |
| US10668028B2 (en) | Methods and use of inducing apoptosis in cancer cells | |
| EA030208B1 (ru) | Система хранения и дозирования множества точно отмеренных стандартных доз крема имиквимода | |
| CN104922130B (zh) | 一种用于治疗带状疱疹的凝胶剂及其制备方法 | |
| US6407125B1 (en) | Pharmacological agent and method of treatment | |
| AU781066B2 (en) | Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof | |
| WO2002020486A2 (en) | Picolinic acid derivatives for the prevention and treatment of cancer in animals | |
| US20210196676A1 (en) | Treatment of viral infections and virally associated lesions with sequiterpene lactones | |
| US20180133239A1 (en) | Therapeutic composition | |
| WO2022206086A1 (zh) | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 | |
| JP4903057B2 (ja) | いぼをテルル化合物により治療するための治療法および医薬組成物 | |
| RU2545918C1 (ru) | Лечение вирусных инфекций | |
| US6441009B1 (en) | Agent and method of preventing and treating heavy metal exposure and toxicity | |
| CN101612203B (zh) | 一种用于治疗尖锐湿疣的中药组合物及其应用 | |
| AU2017223970B2 (en) | Method and composition for treating cancer or skin lesion using a vaccine | |
| KR101671484B1 (ko) | 오셀타미비르(Oseltamivir)를 포함하는 인유두종 바이러스 치료용 약학적 조성물 | |
| CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
| US20060009401A1 (en) | Method for treatment and prevention of herpes zoster by topical application | |
| WO2012070967A1 (ru) | Ранозаживляющая, противоожоговая, регенерирующая и противовирусная фармацевтическая композиция для местного применения | |
| Scheinberg | Stopping skin assailants: fungi, yeasts, and viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22778275 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280006407.8 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |